Fingolimod (FTY720, Gilenya) and its phosphorylated form (phosphorylated by SphK, p-FTY720) are clinically used as treatments to target S1PR1,3-5, but not S1PR2, for the treatment of autoimmune diseases such as multiple sclerosis (MS) by sequestering lymphocytes in lymph nodes and therefore attenuating the migration of inflammatory lymphocytes into inflamed sites31. This evidence concerns the gene S1PR1 and myeloid sarcoma.